Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. (Q42141287)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

main subject

phase II clinical trial

0 references

author

Adrian Paul Mander

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

S G Thompson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

1 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

Contemporary Clinical Trials

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

572-578

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

9 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

A predictive probability design for phase II cancer clinical trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

Proper inference from Simon's two-stage designs

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

Randomized phase II designs in cancer clinical trials: current status and future directions

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

Admissible two-stage designs for phase II cancer clinical trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

How large should a phase II trial of a new drug be?

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

Optimal two-stage designs for phase II clinical trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

A Multiple Testing Procedure for Clinical Trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

Curtailed two-stage designs in Phase II clinical trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

Adaptive two-stage designs for single-arm phase IIA cancer clinical trials

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

Optimal two-stage designs for single arm phase II cancer trials.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

A modification of Simon's optimal design for phase II trials when the criterion is median sample size

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049867

Improved confidence intervals for a binomial parameter following a group sequential phase II clinical trial

17 August 2018

1 reference

12 December 2020

One-sample multiple testing procedure for phase II clinical trials

1 reference

12 December 2020

Optimal three-stage designs for phase II cancer clinical trials

1 reference

12 December 2020

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

1 reference

12 December 2020

Balanced two-stage designs for phase II clinical trials

1 reference

12 December 2020

Optimal and minimax three-stage designs for phase II oncology clinical trials

1 reference

12 December 2020

10.1016/J.CCT.2010.07.008

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20678585%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

20678585

1 reference